Ritesh R. Kotecha, MD
Genitourinary Medical Oncologist & Cellular Therapist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Genitourinary Cancers, Kidney Cancers, Bladder Cancer, Prostate Cancer, Testicular Cancer, Clinical Trials, Cellular Immunotherapy
Request an Appointment
About Me
- Assistant Attending Physician
I am a medical oncologist specializing in the care of people with genitourinary (GU) cancers, including kidney cancer, bladder cancer, prostate cancer, and testicular cancer.
At Memorial Sloan Kettering Cancer Center (MSK), I work with an excellent team of surgeons, radiation oncologists, and nurses. Together, we create personalized treatment plans for our patients. My goal as a physician is to balance treatment with a patient’s quality of life. Overall, I am a strong believer in patient education and shared decision-making.
Read more
I am an active clinical and translational researcher within MSK’s Genitourinary Oncology Service, which seeks to advance our field’s understanding of GU cancers to optimize novel treatments. I lead and participate in clinical trials investigating new interventions and therapies for patients with GU cancers.
Much of my research centers on the innovation of novel treatment options for patients with kidney cancer. I collaborate with other clinical researchers and scientists at MSK to understand the distinct genetic and molecular changes that occur in kidney cancers; we use these insights to better develop targeted treatment strategies and immunotherapies. To that end, I research biomarkers that can help us predict which patients will respond to different immunotherapies and focus my efforts on designing and engineering cellular immunotherapies.
A genitourinary (jeh-nih-toh-YOOR-ih-nayr-ee) medical oncologist is a cancer doctor who specializes in genitourinary (GU) cancers. This includes bladder, kidney, penis, prostate, and testicular cancers.
A cellular therapy specialist is a doctor with special training in using cell therapies to treat health conditions such as cancer. Therapies can include chimeric antigen receptor (CAR) T cell therapy.
My Specialties
- Genitourinary Cancers, Kidney Cancers, Bladder Cancer, Prostate Cancer, Testicular Cancer, Clinical Trials, Cellular Immunotherapy
Education
- MD, Albany Medical College
Residencies
- Internal Medicine - Beth Israel Deaconess Medical Center
Awards and Honors
- Academy of Kidney Cancer Investigator Inductee, Kidney Cancer Research Program of the Department of Defense (2021)
- Young Investigator Award, Kidney Cancer Association (2020)
- Young Investigator Award, Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO, 2019)
- Chief Oncology Fellow, Memorial Sloan Kettering Cancer Center (2017)
Fellowships
- Medical Oncology/Hematology - Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine
- Medical Oncology
- Hematology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Kotecha sees patients at three locations.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Kotecha
- A Phase 1 Study of XmAb819 in People with Kidney Cancer
- A Phase 1/2 Study of AB-2100 Cellular Therapy in People With Advanced Clear Cell Renal Cell Carcinoma
- A Phase 1B Study of Cabozantinib and Nivolumab Immunotherapy With Radiation Therapy to Treat Kidney Cancer That Spread to the Brain
- A Phase I Study of ALLO-647 and ALLO-316 CAR T-Cell Therapy in People with Advanced Kidney Cancer
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Kotecha’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Ritesh R. Kotecha discloses the following relationships and financial interests:
-
Allogene Therapeutics
Professional Services and Activities (Uncompensated) -
Arsenal Biosciences, Inc.
Professional Services and Activities (Uncompensated) -
Eisai
Professional Services and Activities -
Exelixis
Professional Services and Activities (Uncompensated) -
Guidepoint Global Advisors
Professional Services and Activities
-
Kaplan, Inc.
Professional Services and Activities -
Kidney Cancer Journal
Professional Services and Activities -
Novartis
Professional Services and Activities (Uncompensated) -
Pfizer, Inc.
Professional Services and Activities (Uncompensated) -
Xencor, Inc.
Professional Services and Activities (Uncompensated)
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].